Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease

Brain tissue from normal individuals with incidental Lewy bodies and cell loss in pigmented substantia nigra neurons (asymptomatic Parkinson's disease) and age‐matched control subjects without nigral Lewy bodies was examined biochemically. There was no difference in dopamine levels or dopamine turnover in the caudate and putamen of individuals with incidental Lewy body disease compared to control subjects. There were no differences in levels of iron, copper, manganese, or zinc in the substantia nigra or other brain regions from the individuals with incidental Lewy body disease compared to those from control subjects. Similarly, ferritin levels in the substantia nigra and other brain areas were unaltered. There was no difference in the activity of succinate cytochrome c reductase (complexes II and III) or cytochrome oxidase (complex IV) between incidental Lewy body subjects and control subjects. Rotenone‐sensitive NADH coenzyme Q1 reductase activity (complex I) was reduced to levels intermediate between those in control subjects and those in patients with overt Parkinson's disease, but this change did not reach statistical significance. The levels of reduced glutathione in substantia nigra were reduced by 35% in patients with incidental Lewy body disease compared to control subjects. Reduced glutathione levels in other brain regions were unaffected and there were no changes in oxidized glutathione levels in any brain region. Altered iron metabolism is not detectable in the early stages of nigral dopamine cell degeneration. There may be some impairment of mitochondrial complex I activity in the substantia nigra in Parkinson's disease. The marked reduction in nigral reduced glutathione levels suggests this to be an important early change in the process of oxidative stress underlying Parkinson's disease.

[1]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[2]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[3]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[4]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[5]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[6]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[7]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[8]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[9]  S. Ohta,et al.  Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.

[10]  C. Marsden,et al.  Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. , 1989, Biochemical pharmacology.

[11]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[12]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[13]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[14]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[15]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[16]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[17]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[18]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[19]  Arthur J. L. Cooper,et al.  Glutathione and Ascorbate During Ischemia and Postischemic Reperfusion in Rat Brain , 1980, Journal of neurochemistry.

[20]  D. J. Reed,et al.  High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides. , 1980, Analytical biochemistry.

[21]  L. Forno,et al.  CONCENTRIC HYALIN INTRANEURONAL INCLUSIONS OF LEWY TYPE IN THE BRAINS OF ELDERLY PERSONS (50 INCIDENTAL CASES): RELATIONSHIP TO PARKINSONISM , 1969, Journal of the American Geriatrics Society.

[22]  F. Tietze Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.

[23]  H. Sies,et al.  Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. , 1981, Methods in enzymology.

[24]  W. Gibb,et al.  Occasional Review , 2022 .